{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:42:52Z","timestamp":1755794572533,"version":"3.44.0"},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,8,15]]},"DOI":"10.2169\/internalmedicine.4791-24","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:11:45Z","timestamp":1738948305000},"page":"2500-2505","source":"Crossref","is-referenced-by-count":0,"title":["Serum Soluble Interleukin-2 Receptor as a Potential Marker for Assessing Disease Activity in the TAFRO Subtype of Idiopathic Multicentric Castleman Disease"],"prefix":"10.2169","volume":"64","author":[{"given":"Takashi","family":"Ozaki","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Imada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shirakami","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasuku","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Shingai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhito","family":"Umeki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oita Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood 135: 1353-1364, 2020.","DOI":"10.1182\/blood.2019000931"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gao YH, Liu YT, Zhang MY, et al. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. Br J Haematol 204: 1830-1837, 2024.","DOI":"10.1111\/bjh.19334"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fajgenbaum DC, Pierson SK, Kanhai K, et al.; the ACCELERATE Registry Team. The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. Br J Haematol 198: 307-316, 2022.","DOI":"10.1111\/bjh.18214"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Masaki Y, Ueda Y, Yanagisawa H, et al. TAFRO syndrome: a disease requiring immediate medical attention. Intern Med 62: 27-32, 2023.","DOI":"10.2169\/internalmedicine.9622-22"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kanda N, Yamaguchi R, Yamamoto Y, Matsumura M, Hatakeyama S. Performance of serum soluble interleukin-2 receptor as a diagnostic marker for lymphoma in patients with fever. Sci Rep 13: 18784, 2023.","DOI":"10.1038\/s41598-023-44123-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Damoiseaux J. The IL-2-IL-2 receptor pathway in health and disease: the role of the soluble IL-2 receptor. Clin Immunol 218: 108515, 2020.","DOI":"10.1016\/j.clim.2020.108515"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fujimoto S, Sakai T, Kawabata H, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94: 975-983, 2019.","DOI":"10.1002\/ajh.25554"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fajgenbaum DC, Langan RA, Japp AS, et al. Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest 129: 4451-4463, 2019.","DOI":"10.1172\/JCI126091"},{"key":"9","doi-asserted-by":"crossref","first-page":"e135031","DOI":"10.1172\/jci.insight.135031","volume":"5","author":"RL Pai","year":"2020","unstructured":"9. Pai RL, Japp AS, Gonzalez M, et al. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight 5: e135031, 2020.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rubenstein AI, Pierson SK, Shyamsundar S, et al. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. Br J Haematol 204: 921-930, 2024.","DOI":"10.1111\/bjh.19279"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yamaguchi Y, Maeda Y, Shibahara T, et al. Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review. Mod Rheumatol Case Rep 4: 302-309, 2020.","DOI":"10.1080\/24725625.2020.1717747"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yamamoto S, Wells K, Morita K, et al. Severe TAFRO syndrome mimicking hepatorenal syndrome successfully treated with a multidisciplinary approach: a case report and literature review. Intern Med 62: 2715-2724, 2023.","DOI":"10.2169\/internalmedicine.1178-22"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Maisonobe L, Bertinchamp R, Damian L, et al. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort. Br J Haematol 196: 599-605, 2022.","DOI":"10.1111\/bjh.17868"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Fujimoto S, Kawabata H, Sakai T, et al. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. Int J Hematol 113: 73-80, 2021.","DOI":"10.1007\/s12185-020-03008-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lomas OC, Streetly M, Pratt G, et al.; the British Society for Haematology (BSH) Committee. The management of Castleman disease. Br J Haematol 195: 328-337, 2021.","DOI":"10.1111\/bjh.17688"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review. Ann Hematol 99: 2463-2475, 2020.","DOI":"10.1007\/s00277-020-04275-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Koga T, Kawakami A. Interleukin-6 inhibition in the treatment of autoinflammatory diseases. Front Immunol 13: 956795, 2022.","DOI":"10.3389\/fimmu.2022.956795"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/16\/64_4791-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T03:43:25Z","timestamp":1755315805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/16\/64_4791-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":17,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4791-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"4791-24"}}